Clinical Trial Update: FMXIN002 in Patients at Risk of Anaphylaxis [Phase 2, Phase 3]

View source ↗

Summary

Nasus Pharma reports ongoing Phase 2 and Phase 3 clinical trials of FMXIN002 for individuals at risk of anaphylaxis due to food. Enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaphylaxis
• Food Allergy

Drugs mentioned

• FMXIN002

Snippet

Sponsor: Nasus Pharma | Conditions: Anaphylaxis Food | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION